GENI — Genincode Share Price
Last trade - 00:00- £12.34m
- £11.40m
- £2.70m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.95 | ||
| Price to Tang. Book | 12.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -399.22% | ||
| Return on Equity | -367.05% | ||
| Operating Margin | -190.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.96 | 1.15 | 1.43 | 2.16 | 2.7 | 4.3 | n/a | 29.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 6th, 2018
- Public Since
- July 22nd, 2021
- No. of Employees
- 36
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 286,882,042
- Address
- 1 St. Peters Square, OXFORD, OX4 4GP
- Web
- https://www.genincode.com/
- Phone
- +44 1865955847
- Auditors
- Crowe U.K. LLP
Latest News for GENI
Upcoming Events for GENI
Half Year 2025 Genincode PLC Earnings Release
Half Year 2025 Genincode PLC Earnings Presentation
Half Year 2025 Genincode PLC Earnings Presentation (Q&A)
Similar to GENI
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 20:46 UTC, shares in Genincode are trading at 4.30p. This share price information is delayed by 15 minutes.
Shares in Genincode last closed at 4.30p and the price had moved by -23.56% over the past 365 days. In terms of relative price strength the Genincode share price has underperformed the FTSE All Share Index by -30.65% over the past year.
The overall consensus recommendation for Genincode is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGenincode does not currently pay a dividend.
Genincode does not currently pay a dividend.
Genincode does not currently pay a dividend.
To buy shares in Genincode you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 4.30p, shares in Genincode had a market capitalisation of £12.34m.
Here are the trading details for Genincode:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GENI
Based on an overall assessment of its quality, value and momentum Genincode is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genincode is 20.00p. That is 365.12% above the last closing price of 4.30p.
Analysts covering Genincode currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genincode. Over the past six months, its share price has outperformed the FTSE All Share Index by +38.93%.
As of the last closing price of 4.30p, shares in Genincode were trading +62.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genincode PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 4.30p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genincode's management team is headed by:
- Bill Rhodes - NEC
- Matthew Walls - CEO
- Paul Foulger - CFO